Investments, Funding & Disinvestment

McKesson expects the acquisition to strengthen its oncology and multi-specialty strategy while broadening the services it provides to biopharmaceutical companies.

The agreement covers 129 countries, including all African nations, and gives Aspen rights across both public and private healthcare sectors.

Minapharm’s candidate is the fifth Bundibugyo-specific vaccine supported by CEPI as the Democratic Republic of the Congo (DRC) responds to a rapidly escalating outbreak.

Hanmi is developing the HM17321 therapy as a potential first-in-class treatment that could promote weight loss while helping preserve lean body mass.

Seralutinib is an investigational treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Construction of the Hillsboro facility is expected to create about 200 jobs, with workers remaining on site through the project’s anticipated completion in 2031.

Siemens Healthineers will contribute US$5.4 million in cost sharing, bringing the total potential investment to US$36.5 million.

Previously, patients requiring tests unavailable at the hospital had to wait while their samples were transported to facilities in Mbarara.

The investment at Naivasha SEZ is expected to contribute to technology transfer, skills development and job creation while strengthening Kenya’s pharmaceutical manufacturing capacity.

The ICG will allocate 20,000 doses to a Phase 3 clinical trial designed to assess whether Ervebo can protect people against Bundibugyo virus.